ArticleHealth physics2018
PEGylated IL-11 (BBT-059): A Novel Radiation Countermeasure for Hematopoietic Acute Radiation Syndrome.
Article in Health physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Expanding the Treatment Window for the FDA-Approved Radiation Countermeasure Nplate.Military medicine · 2026Article
- Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-059.Radiation research · 2026Article
- LA-GM-CSF, a Long-Acting Cytokine Mitigates and Prevents H-ARS Mediated Lethality in Mice Exposed to Total Body Gamma Radiation.International journal of molecular sciences · 2026Article
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- JNJ-26366821 Attenuates Radiation-Induced Pro-Inflammatory Cytokines and miRNAs and Triggers TR/RXR Signaling Pathway.International journal of molecular sciences · 2026Article
- Radiation emergency medical countermeasures: Current formulary, identified gaps, and future approaches.Animal models and experimental medicine · 2025Review
- Advanced Medical Countermeasures and Devices for Use During a Radiological or Nuclear Emergency.Disaster medicine and public health preparedness · 2025Review
- Radiation-induced intestinal injury: from molecular mechanisms to clinical translation.Oncology reviews · 2025Review
- Ionizing Radiation Dose Differentially Affects the Host-Microbe Relationship over Time.Microorganisms · 2024Article
- Pharmacokinetic and Metabolomic Studies with a Promising Radiation Countermeasure, BBT-059 (PEGylated interleukin-11), in Rhesus Nonhuman Primates.Radiation research · 2024Article
- PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury.Scientific reports · 2023Article
- PrC-210 Protects against Radiation-Induced Hematopoietic and Intestinal Injury in Mice and Reduces Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Article
- Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia.Therapeutic advances in hematology · 2023Review
- The delayed effects of acute radiation exposure (DEARE): characteristics, mechanisms, animal models, and promising medical countermeasures.International journal of radiation biology · 2023Review
- CDX-301 prevents radiation-induced dysregulation of miRNA expression and biogenesis.Molecular therapy. Nucleic acids · 2022Article
- Article
- Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821).Scientific reports · 2022Article
- Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes.Frontiers in pharmacology · 2021Article
- RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice.Frontiers in pharmacology · 2021Article
- Delayed effects of acute whole body lethal radiation exposure in mice pre-treated with BBT-059.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-11 was developed to reduce chemotherapy-induced thrombocytopenia; however, its clinical use was limited by severe adverse effects in humans. PEGylated interleukin-11 (BBT-059), developed by Bolder Biotechnology, Inc., exhibited a longer half-life in rodents and induced longer-lasting increases in hematopoietic cells than interleukin-11. A single dose of 1.2 mg kg of BBT-059, administered subcutaneously to CD2F1 mice (12-14 wk, male) was found to be safe in a 14 d toxicity study. The drug demonstrated its efficacy both as a prophylactic countermeasure and a mitigator in CD2F1 mice exposed to Co gamma total-body irradiation. A single dose of 0.3 mg kg, administered either 24 h pre-, 4 h post-, or 24 h postirradiation increased the survival of mice to 70-100% from lethal doses of radiation. Preadministration (-24 h) of the drug conferred a significantly (p < 0.05) higher survival compared to 24 h post-total-body irradiation. There was significantly accelerated recovery from radiation-induced peripheral blood neutropenia and thrombocytopenia in animals pretreated with BBT-059. The drug also increased bone marrow cellularity and megakaryocytes and accelerated multilineage hematopoietic recovery. In addition, BBT-059 inhibited the induction of radiation-induced hematopoietic biomarkers, thrombopoietin, erythropoietin, and Flt-3 ligand. These results indicate that BBT-059 is a promising radiation countermeasure, demonstrating its potential to be used both pre- and postirradiation for hematopoietic acute radiation syndrome with a broad window for medical management in a radiological or nuclear event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.